It helps detoxify cells, lighten pigmentation, and improve immunity
For a medication protocol that requires titration management and side effect oversight, that's a real differentiator from platforms that offer one intake consultation and ship medication without ongoing support
approvals: T2D (Mounjaro, 2022), obesity (Zepbound, 2023), and obstructive sleep apnea with obesity (Zepbound, 2024) Ongoing Innovations in GLP-1s Landscape The obesity pipeline from phase 1 to market now includes 173 drugs, with GLP-1 and combination therapies accounting for majority of trials
Semaglutide is not a controlled substance and is not currently part of any military testing expansion
Pharmacol Res 133:218235
While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study